ALMR

SCHEDULE 13G - Alamar Biosciences, Inc. (0002104204) (Subject)

10-Q - Alamar Biosciences, Inc. (0002104204) (Filer)

8-K - Alamar Biosciences, Inc. (0002104204) (Filer)

FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended June 30, 2026. Recent Highlights Generated $29.4 million of total revenue for the second quarter of 2026, an increase of 82% as compared to the corresponding period of 2025Launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau, available in our NULISAseq™ Neuro 220 Panel and through our Technology Access Program, enabling scalable, non-invasive measurement of tau tangle burdenExpanded strategic partnership with the Alzheimer's Dise

Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers toward a precision-medicine understanding of disease heterogeneity, subtypes, and trajectories Combined dataset, projected for completion in 2027, expected to represent the largest study of neurodegenerative disease, encompassing more than 140,000 samples across diverse geographies and cohorts FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced an expansion of its strategic partnership with the Alzhe

Fremont, CA, July 28, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the launch of the NULISAseq™ Immune 340 Panel, its broadest multiplexed immune profiling solution available for translational research and drug development. The panel expands on the NULISAseq Inflammation Panel 250, to deliver simultaneous measurement of approximately 340 immune-related proteins from a single sample.  By measuring key proteins that were previously undetectable by other methods, the Immune 340 Panel deepens the understanding of the immune proteome in critical disease areas across cancer

8-K - Alamar Biosciences, Inc. (0002104204) (Filer)

FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report financial results for the second quarter 2026 after market close on Monday, August 10, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.alamarbio.com. The webcast will be archived and available for replay after the event. About Alamar Biosciences Alamar is a commercial-stage proteomics company est

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a partnership with leading research universities to launch a national-scale proteomics initiative using Alamar Biosciences’ NULISAseq Neuro 220 panel to accelerate biomarker discovery and validation for Alzheimer’s disease and related neurodegenerative conditions. The project is co-led by professors Sarah Biber, PhD, at Washington University in St. Louis; Sterling Johnson, PhD, at the University of Wisconsin; and Tatiana Foroud, PhD, director of the National Centralized Repository for Alzheimer’s D

SCHEDULE 13D/A - Alamar Biosciences, Inc. (0002104204) (Subject)

Fremont, CA, July 07, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the first commercial eMTBR-Tau immunoassay, now available in the NULISAseq™ Neuro 220 multiplexed panel kits, immediately deployable on the entire installed base of ARGO™ HT instruments, and as a single-plex assay through the company’s Technology Access Program (TAP). The assay measures eMTBR-Tau, a plasma biomarker that specifically reflects tau tangle pathology and has demonstrated strong associations with cognitive decline, clinical disease staging, and therapeutic response monitoring for Alzheimer

SCHEDULE 13G - Alamar Biosciences, Inc. (0002104204) (Subject)

Fremont, CA, June 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today launched the NULISA™ Dried Blood Spot (DBS) Extraction Kit, enabling researchers to run NULISA assays on microsamples collected at home, unlocking longitudinal and decentralized translational study designs in neurology, inflammation, and population health that cannot be supported by venous blood draws alone. "This launch reflects our commitment to making proteomics more accessible for population-based screening programs," said Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. "By comb

Analyst initiated coverage of Alamar Biosciences with a rating of Overweight and set a new price target of $30.00

BofA Securities initiated coverage of Alamar Biosciences with a rating of Neutral and set a new price target of $27.00

TD Cowen initiated coverage of Alamar Biosciences with a rating of Buy and set a new price target of $30.00

Leerink Partners initiated coverage of Alamar Biosciences with a rating of Outperform and set a new price target of $35.00

Stifel initiated coverage of Alamar Biosciences with a rating of Buy and set a new price target of $28.00

10-Q - Alamar Biosciences, Inc. (0002104204) (Filer)

8-K - Alamar Biosciences, Inc. (0002104204) (Filer)

FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025.Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research.Raised approximately $220 million in gross proceeds from our initial public offering in April 2026. "We began 2026 with a record quarter

FREMONT, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will be participating in the upcoming BofA Securities 2026 Healthcare Conference in Las Vegas, Nevada. Alamar Biosciences' management is scheduled to present on Tuesday, May 12, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the "Investors" section of the company website at investors.alamarbio.com. About Alamar Biosciences, Inc. Alamar is a life sciences company dedicated to powering Precision Proteomics to enab

FREMONT, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will publish its first quarter 2026 financial results before market open on Friday, May 8, 2026. Alamar Biosciences plans to host and webcast its first earnings conference call as a public company in August 2026 to report second quarter 2026 financial results. About Alamar Biosciences, Inc. Alamar is a life sciences company dedicated to powering Precision Proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's

SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)

SCHEDULE 13D - Alamar Biosciences, Inc. (0002104204) (Subject)